ANCN - Anchiano Therapeutics Ltd

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
9.30
+0.10 (+1.09%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close9.20
Open9.20
Bid9.10 x 900
Ask9.44 x 1000
Day's Range9.08 - 9.37
52 Week Range8.72 - 11.50
Volume30,740
Avg. Volume278,233
Market Cap52.246M
Beta (3Y Monthly)0.58
PE Ratio (TTM)N/A
EPS (TTM)-1.19
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering

    Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has closed its initial public offering of 2,652,174 of its American Depositary Shares (“ADSs”), each representing five ordinary shares of Anchiano, at $11.50 per ADS resulting in gross proceeds of $30.5 million. The ADSs began trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN” on February 12, 2019. The underwriters have been granted a 30-day option to purchase up to an additional 397,826 ADSs offered by Anchiano to cover over-allotments, if any.

  • MarketWatch3 days ago

    Anchiano Therapeutics' stock set to close well below its IPO price

    Shares of Anchiano Therapeutics Ltd. was on track to close below its initial public offering price on its debut, bucking the gains in its Nasdaq biotechnology peers and the broader stock market. The stock's first trade was at its IPO price of $11.50 at 10:02 a.m. Eastern, and that was the highest price it traded. The Israel-based biotechnology company's stock fell as much as 8.3% below its IPO price, at the intraday low of $10.55, but has pared some losses to be down 6.4% in recent trade. Meanwhile, the iShares Nasdaq Biotechnology ETF was up 0.9% in afternoon trade while the S&P 500 was rallying 1.3%.

  • MarketWatch4 days ago

    Anchiano Therapeutics IPO prices below assumed price

    Israel-based Anchiano Therapeutics Ltd. said Tuesday said the initial public offering of American Depositary Shares had priced at $11.50 each. With the biotechnology company is offering 2,652,174 ADS to raise $30.5 million, and could raise up to $35.1 million if options granted to underwriters are exercised. The company had previously said it assumed an initial public offering price of $14.55 per ADS. The stock is expected to begin trading Tuesday on the Nasdaq Capital Market under the ticker symbol "ANCN." The company's lead underwriters are Oppenheimer and Ladenburg Thalmann. The company is going public at a time that iShares Nasdaq Biotechnology ETF has gained 3.7% over the past three months through Monday and the Renaissance IPO ETF has rallied 7.8%, while the S&P 500 has slipped 0.6%.

  • GlobeNewswire4 days ago

    Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering

    Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has priced its initial public offering of 2,652,174 of its American Depositary Shares (“ADSs”), each representing five ordinary shares of Anchiano, at $11.50 per ADS, less underwriting discounts and commissions. The ADSs are expected to begin trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN” on February 12, 2019, and the offering is expected to close on or about February 14, 2019. The underwriters have been granted a 30-day option to purchase up to an additional 397,826 ADSs offered by Anchiano to cover over-allotments, if any.

  • Benzinga5 days ago

    IPO Outlook For The Week: Biotechs And Another Virgin Group Addition

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Anchiano Therapeutics Ltd. (ANCN) will issue 2.4 million shares at $14.55 ...